Dimeric FcgR ectodomains as probes of the Fc receptor function of anti-influenza virus IgG

Journal of Immunology

Volumn 197, Issue 4, 2016, Pages 1507-1516

  Wines, Bruce D ^a,b,c   Vanderven, Hillary A ^c   Esparon, Sandra E ^a   Kristensen, Anne B ^c   Kent, Stephen J ^b,c   Hogarth, P Mark ^a,b,c  

^a BURNET INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN G ANTIBODY; ANTIGEN ANTIBODY COMPLEX; IMMUNOGLOBULIN G; VIRUS ANTIBODY;

2009 H1N1 INFLUENZA; ANTIBODY TITER; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; HUMAN; INFLUENZA A VIRUS (H1N1); LIMIT OF QUANTITATION; LYMPHOCYTE ACTIVATION; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BINDING ASSAY; ANTIGEN ANTIBODY COMPLEX; IMMUNOLOGICAL TECHNIQUE; IMMUNOLOGY; PROCEDURES;

ANTIBODIES, VIRAL; ANTIGEN-ANTIBODY COMPLEX; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC TECHNIQUES; INFLUENZA A VIRUS, H1N1 SUBTYPE; RECEPTORS, FC; RECEPTORS, IGG;

EID: 84983751890     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1502551     Document Type: Article

References (74)

1. Pollara, J., M. Bonsignori, M. A. Moody, M. Pazgier, B. F. Haynes, and G. Ferrari. 2013. Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses. Curr. HIV Res. 11: 378-387.
2. Kohl, S. 1991. Role of antibody-dependent cellular cytotoxicity in defense against herpes simplex virus infections. Rev. Infect. Dis. 13: 108-114.
3. Hashimoto, G., P. F. Wright, and D. T. Karzon. 1983. Antibody-dependent cellmediated cytotoxicity against influenza virus-infected cells. J. Infect. Dis. 148: 785-794.
4. Petro, C., P. A. González, N. Cheshenko, T. Jandl, N. Khajoueinejad, A. Bénard, M. Sengupta, B. C. Herold, and W. R. Jacobs. 2015. Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease. eLife 4: 4.
5. Kramski, M., M. S. Parsons, I. Stratov, and S. J. Kent. 2013. HIV-specific antibody immunity mediated through NK cells and monocytes. Curr. HIV Res. 11: 388-406.
6. Jegaskanda, S., P. C. Reading, and S. J. Kent. 2014. Influenza-specific antibodydependent cellular cytotoxicity: Toward a universal influenza vaccine. J. Immunol. 193: 469-475.
7. Jegaskanda, S., J. T. Weinfurter, T. C. Friedrich, and S. J. Kent. 2013. Antibodydependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques. J. Virol. 87: 5512-5522.
8. Hessell, A. J., L. Hangartner, M. Hunter, C. E. Havenith, F. J. Beurskens, J. M. Bakker, C. M. Lanigan, G. Landucci, D. N. Forthal, P. W. Parren, et al. 2007. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449: 101-104.
9. Bournazos, S., F. Klein, J. Pietzsch, M. S. Seaman, M. C. Nussenzweig, and J. V. Ravetch. 2014. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell 158: 1243-1253.
10. Bonsignori, M., J. Pollara, M. A. Moody, M. D. Alpert, X. Chen, K. K. Hwang, P. B. Gilbert, Y. Huang, T. C. Gurley, D. M. Kozink, et al. 2012. Antibodydependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J. Virol. 86: 11521-11532.
11. Bialuk, I., S. Whitney, V. Andresen, R. H. Florese, J. Nacsa, V. Cecchinato, V. W. Valeri, J. M. Heraud, S. Gordon, R. W. Parks, et al. 2011. Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques. Vaccine 30: 78-94.
12. DiLillo, D. J., G. S. Tan, P. Palese, and J. V. Ravetch. 2014. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgR interactions for protection against influenza virus in vivo. Nat. Med. 20: 143-151.
13. Throsby, M., E. van den Brink, M. Jongeneelen, L. L. Poon, P. Alard, L. Cornelissen, A. Bakker, F. Cox, E. van Deventer, Y. Guan, et al. 2008. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 3: E3942.
14. Impagliazzo, A., F. Milder, H. Kuipers, M. V. Wagner, X. Zhu, R. M. Hoffman, R. van Meersbergen, J. Huizingh, P. Wanningen, J. Verspuij, et al. 2015. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 349: 1301-1306.
15. DiLillo, D. J., P. Palese, P. C. Wilson, and J. V. Ravetch. 2016. Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J. Clin. Invest. 126: 605-610.
16. Hobson, D., R. L. Curry, A. S. Beare, and A. Ward-Gardner. 1972. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J. Hyg. (Lond.) 70: 767-777.
17. Huber, V. C., J. M. Lynch, D. J. Bucher, J. Le, and D. W. Metzger. 2001. Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J. Immunol. 166: 7381-7388.
18. Jegaskanda, S., E. R. Job, M. Kramski, K. Laurie, G. Isitman, R. de Rose, W. R. Winnall, I. Stratov, A. G. Brooks, P. C. Reading, and S. J. Kent. 2013. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J. Immunol. 190: 1837-1848.
19. Hung, I. F., K. K. To, C. K. Lee, K. L. Lee, W. W. Yan, K. Chan, W. M. Chan, C. W. Ngai, K. I. Law, F. L. Chow, et al. 2013. Hyperimmune IV immunoglobulin treatment: A multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest 144: 464-473.
20. Chung, A. W., M. P. Kumar, K. B. Arnold, W. H. Yu, M. K. Schoen, L. J. Dunphy, T. J. Suscovich, N. Frahm, C. Linde, A. E. Mahan, et al. 2015. Dissecting polyclonal vaccine-induced humoral immunity against HIV using systems serology. Cell 163: 988-998.
21. Amigorena, S., D. Lankar, V. Briken, L. Gapin, M. Viguier, and C. Bonnerot. 1998. Type II and III receptors for immunoglobulin G (IgG) control the presentation of different T cell epitopes from single IgG-complexed antigens. J. Exp. Med. 187: 505-515.
22. Dhodapkar, K. M., J. L. Kaufman, M. Ehlers, D. K. Banerjee, E. Bonvini, S. Koenig, R. M. Steinman, J. V. Ravetch, and M. V. Dhodapkar. 2005. Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc. Natl. Acad. Sci. USA 102: 2910-2915.
23. Maglione, P. J., J. Xu, A. Casadevall, and J. Chan. 2008. Fc gamma receptors regulate immune activation and susceptibility during Mycobacterium tuberculosis infection. J. Immunol. 180: 3329-3338.
24. DiLillo, D. J., and J. V. Ravetch. 2015. Differential Fc-receptor engagement drives an anti-tumor vaccinal effect. Cell 161: 1035-1045.
25. Oppenheim, D. E., R. Spreafico, A. Etuk, D. Malone, E. Amofah, C. Peña- Murillo, T. Murray, L. McLaughlin, B. S. Choi, S. Allan, et al. 2014. Glycoengineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy. Br. J. Cancer 110: 1221-1227.
26. Sliwkowski, M. X., and I. Mellman. 2013. Antibody therapeutics in cancer. Science 341: 1192-1198.
27. Lu, J., J. Chu, Z. Zou, N. B. Hamacher, M. W. Rixon, and P. D. Sun. 2015. Structure of FcgRI in complex with Fc reveals the importance of glycan recognition for high-affinity IgG binding. Proc. Natl. Acad. Sci. USA 112: 833-838.
28. Lu, J., J. L. Ellsworth, N. Hamacher, S. W. Oak, and P. D. Sun. 2011. Crystal structure of Fcg receptor I and its implication in high affinity g-immunoglobulin binding. J. Biol. Chem. 286: 40608-40613.
29. Maxwell, K. F., M. S. Powell, M. D. Hulett, P. A. Barton, I. F. McKenzie, T. P. Garrett, and P. M. Hogarth. 1999. Crystal structure of the human leukocyte Fc receptor, Fc gammaRIIa. Nat. Struct. Biol. 6: 437-442.
30. Ramsland, P. A., W. Farrugia, T. M. Bradford, C. T. Sardjono, S. Esparon, H. M. Trist, M. S. Powell, P. S. Tan, A. C. Cendron, B. D. Wines, et al. 2011. Structural basis for Fc gammaRIIa recognition of human IgG and formation of inflammatory signaling complexes. J. Immunol. 187: 3208-3217.
31. Sondermann, P., R. Huber, and U. Jacob. 1999. Crystal structure of the soluble form of the human fcgamma-receptor IIb: A new member of the immunoglobulin superfamily at 1.7 A resolution. EMBO J. 18: 1095-1103.
32. Radaev, S., S. Motyka, W. H. Fridman, C. Sautes-Fridman, and P. D. Sun. 2001. The structure of a human type III Fcgamma receptor in complex with Fc. J. Biol. Chem. 276: 16469-16477.
33. Sondermann, P., R. Huber, V. Oosthuizen, and U. Jacob. 2000. The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature 406: 267-273.
34. Hogarth, P. M., and G. A. Pietersz. 2012. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat. Rev. Drug Discov. 11: 311-331.
35. Albanesi, M., and M. Daëron. 2012. The interactions of therapeutic antibodies with Fc receptors. Immunol. Lett. 143: 20-27.
36. Nesspor, T. C., T. S. Raju, C. N. Chin, O. Vafa, and R. J. Brezski. 2012. Avidity confers FcgR binding and immune effector function to aglycosylated immunoglobulin G1. J. Mol. Recognit. 25: 147-154.
37. Bruhns, P., B. Iannascoli, P. England, D. A. Mancardi, N. Fernandez, S. Jorieux, and M. Daëron. 2009. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 113: 3716-3725.
38. Lux, A., X. Yu, C. N. Scanlan, and F. Nimmerjahn. 2013. Impact of immune complex size and glycosylation on IgG binding to human FcgRs. J. Immunol. 190: 4315-4323.
39. Acharya, P., W. D. Tolbert, N. Gohain, X. Wu, L. Yu, T. Liu, W. Huang, C. C. Huang, Y. D. Kwon, R. K. Louder, et al. 2014. Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection. J. Virol. 88: 12895-12906.
40. Cheng, Z. J., D. Garvin, A. Paguio, R. Moravec, L. Engel, F. Fan, and T. Surowy. 2014. Development of a robust reporter-based ADCC assay with frozen, thawand- use cells to measure Fc effector function of therapeutic antibodies. J. Immunol. Methods 414: 69-81.
41. Chung, S., Y. L. Lin, C. Reed, C. Ng, Z. J. Cheng, F. Malavasi, J. Yang, V. Quarmby, and A. Song. 2014. Characterization of in vitro antibody-dependent cell-mediated cytotoxicity activity of therapeutic antibodies - impact of effector cells. J. Immunol. Methods 407: 63-75.
42. Iida, S., R. Kuni-Kamochi, K. Mori, H. Misaka, M. Inoue, A. Okazaki, K. Shitara, and M. Satoh. 2009. Two mechanisms of the enhanced antibodydependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood. BMC Cancer 9: 58.
43. Mata, M. M., F. Mahmood, R. T. Sowell, and L. L. Baum. 2014. Effects of cryopreservation on effector cells for antibody dependent cell-mediated cytotoxicity (ADCC) and natural killer (NK) cell activity in (51)Cr-release and CD107a assays. J. Immunol. Methods 406: 1-9.
44. Mishima, Y., Y. Terui, Y. Mishima, R. Kuniyoshi, S. Matsusaka, M. Mikuniya, K. Kojima, and K. Hatake. 2012. High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between FcgRllla polymorphism. Int. Immunol. 24: 477-483.
45. Tada, M., A. Ishii-Watabe, T. Suzuki, and N. Kawasaki. 2014. Development of a cell-based assay measuring the activation of FcgRIIa for the characterization of therapeutic monoclonal antibodies. PLoS One 9: E95787.
46. Howarth, M., K. Takao, Y. Hayashi, and A. Y. Ting. 2005. Targeting quantum dots to surface proteins in living cells with biotin ligase. Proc. Natl. Acad. Sci. USA 102: 7583-7588.
47. Ramsland, P. A., N. Willoughby, H. M. Trist, W. Farrugia, P. M. Hogarth, J. D. Fraser, and B. D.Wines. 2007. Structural basis for evasion of IgA immunity by Staphylococcus aureus revealed in the complex of SSL7 with Fc of human IgA1. Proc. Natl. Acad. Sci. USA 104: 15051-15056.
48. Hibbs, M. L., L. Bonadonna, B. M. Scott, I. F. C. McKenzie, and P. M. Hogarth. 1988. Molecular cloning of a human immunoglobulin G Fc receptor. Proc. Natl. Acad. Sci. USA 85: 2240-2244.
49. Patel, D., B. D. Wines, R. J. Langley, and J. D. Fraser. 2010. Specificity of staphylococcal superantigen-like protein 10 toward the human IgG1 Fc domain. J. Immunol. 184: 6283-6292.
50. Evans, M. J., S. L. Hartman, D. W. Wolff, S. A. Rollins, and S. P. Squinto. 1995. Rapid expression of an anti-human C5 chimeric Fab utilizing a vector that replicates in COS and 293 cells. J. Immunol. Methods 184: 123-138.
51. Petersen, T. N., S. Brunak, G. von Heijne, and H. Nielsen. 2011. SignalP 4.0: discriminating signal peptides from transmembrane regions. Nat. Methods 8: 785-786.
52. Jegaskanda, S., T. H. Amarasena, K. L. Laurie, H. X. Tan, J. Butler, M. S. Parsons, S. Alcantara, J. Petravic, M. P. Davenport, A. C. Hurt, et al. 2013. Standard trivalent influenza virus protein vaccination does not prime antibodydependent cellular cytotoxicity in macaques. J. Virol. 87: 13706-13718.
53. Jegaskanda, S., K. L. Laurie, T. H. Amarasena, W. R. Winnall, M. Kramski, R. De Rose, I. G. Barr, A. G. Brooks, P. C. Reading, and S. J. Kent. 2013. Ageassociated cross-reactive antibody-dependent cellular cytotoxicity toward 2009 pandemic influenza A virus subtype H1N1. J. Infect. Dis. 208: 1051-1061.
54. Jegaskanda, S., K. Vandenberg, K. L. Laurie, L. Loh, M. Kramski, W. R. Winnall, K. Kedzierska, S. Rockman, and S. J. Kent. 2014. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity in intravenous immunoglobulin as a potential therapeutic against emerging influenza viruses. J. Infect. Dis. 210: 1811-1822.
55. Gong, J. H., G. Maki, and H. G. Klingemann. 1994. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8: 652-658.
56. Lund, J., G. Winter, P. T. Jones, J. D. Pound, T. Tanaka, M. R. Walker, P. J. Artymiuk, Y. Arata, D. R. Burton, R. Jefferis, et al. 1991. Human Fc gamma RI and Fc gamma RII interact with distinct but overlapping sites on human IgG. J. Immunol. 147: 2657-2662.
57. Wines, B. D., M. S. Powell, P. W. Parren, N. Barnes, and P. M. Hogarth. 2000. The IgG Fc contains distinct Fc receptor (FcR) binding sites: The leukocyte receptors Fc gamma RI and Fc gamma RIIa bind to a region in the Fc distinct from that recognized by neonatal FcR and protein A. J. Immunol. 164: 5313-5318.
58. Golay, J., F. Da Roit, L. Bologna, C. Ferrara, J. H. Leusen, A. Rambaldi, C. Klein, and M. Introna. 2013. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood 122: 3482-3491.
59. Metzger, H. 1992. Transmembrane signaling: The joy of aggregation. J. Immunol. 149: 1477-1487.
60. Greenberg, S., P. Chang, and S. C. Silverstein. 1994. Tyrosine phosphorylation of the g subunit of Fcg receptors, p72syk, and paxillin during Fc receptor-mediated phagocytosis in macrophages. J. Biol. Chem. 269: 3897-3902.
61. Nimmerjahn, F., S. Gordan, and A. Lux. 2015. FcgR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities. Trends Immunol. 36: 325-336.
62. Glanville, J., W. Zhai, J. Berka, D. Telman, G. Huerta, G. R. Mehta, I. Ni, L. Mei, P. D. Sundar, G. M. Day, et al. 2009. Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire. Proc. Natl. Acad. Sci. USA 106: 20216-20221.
63. Boesch, A. W., E. P. Brown, H. D. Cheng, M. O. Ofori, E. Normandin, P. A. Nigrovic, G. Alter, and M. E. Ackerman. 2014. Highly parallel characterization of IgG Fc binding interactions. MAbs 6: 915-927.
64. Ackerman, M. E., M. Crispin, X. Yu, K. Baruah, A. W. Boesch, D. J. Harvey, A. S. Dugast, E. L. Heizen, A. Ercan, I. Choi, et al. 2013. Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J. Clin. Invest. 123: 2183-2192.
65. Ackerman, M. E., A. S. Dugast, E. G. McAndrew, S. Tsoukas, A. F. Licht, D. J. Irvine, and G. Alter. 2013. Enhanced phagocytic activity of HIV-specific antibodies correlates with natural production of immunoglobulins with skewed affinity for FcgR2a and FcgR2b. J. Virol. 87: 5468-5476.
66. Barouch, D. H., G. Alter, T. Broge, C. Linde, M. E. Ackerman, E. P. Brown, E. N. Borducchi, K. M. Smith, J. P. Nkolola, J. Liu, et al. 2015. Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. Science 349: 320-324.
67. Ackerman, M. E., A. Mikhailova, E. P. Brown, K. G. Dowell, B. D. Walker, C. Bailey-Kellogg, T. J. Suscovich, and G. Alter. 2016. Polyfunctional HIVspecific antibody responses are associated with spontaneous HIV control. PLoS Pathog. 12: E1005315.
68. Brown, E. P., A. F. Licht, A. S. Dugast, I. Choi, C. Bailey-Kellogg, G. Alter, and M. E. Ackerman. 2012. High-throughput, multiplexed IgG subclassing of antigenspecific antibodies from clinical samples. J. Immunol. Methods 386: 117-123.
69. Chung, S., V. Quarmby, X. Gao, Y. Ying, L. Lin, C. Reed, C. Fong, W. Lau, Z. J. Qiu, A. Shen, et al. 2012. Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcg receptor binding and antibody-dependent cellmediated cytotoxicity activities. MAbs 4: 326-340.
70. Chung, A. W., M. Ghebremichael, H. Robinson, E. Brown, I. Choi, S. Lane, A. S. Dugast, M. K. Schoen, M. Rolland, T. J. Suscovich, et al. 2014. Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci. Transl. Med. 6: 228ra38.
71. Dutta, K., A. K. Varshney, M. C. Franklin, M. Goger, X. Wang, and B. C. Fries. 2015. Mechanisms mediating enhanced neutralization efficacy of staphylococcal enterotoxin B by combinations of monoclonal antibodies. J. Biol. Chem. 290: 6715-6730.
72. Bakker, A. B., C. Python, C. J. Kissling, P. Pandya, W. E. Marissen, M. F. Brink, F. Lagerwerf, S. Worst, E. van Corven, S. Kostense, et al. 2008. First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine 26: 5922-5927.
73. Lowy, I., D. C. Molrine, B. A. Leav, B. M. Blair, R. Baxter, D. N. Gerding, G. Nichol, W. D. Thomas Jr., M. Leney, S. Sloan, et al. 2010. Treatment with monoclonal antibodies against Clostridium difficile toxins. N. Engl. J. Med. 362: 197-205.
74. Qiu, X., G. Wong, J. Audet, A. Bello, L. Fernando, J. B. Alimonti, H. Fausther- Bovendo, H. Wei, J. Aviles, E. Hiatt, et al. 2014. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514: 47-53.